| REVIEW ARTICLE |
|
| Year : 2015 | Volume
: 18
| Issue : 5 | Page : 30-34 |
|
|
Newer therapies for multiple sclerosis
Alasdair Coles
Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom
Correspondence Address:
Alasdair Coles
Department of Clinical Neurosciences, Clifford Albutt Building, Level 4, Cambridge Biomedical Campus, CB2 0AH, Cambridge
United Kingdom
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0972-2327.164824
|
|
|
The newer immunotherapies for multiple sclerosis (fingolimod, natalizumab, dimethyl fumarate, teriflunomide, alemtuzumab) offer advantages of efficacy or tolerability over the injectable therapies of the 1990s. But they also have greater risks. As further treatments emerge (daclizumab and ocrelizumab are likely to be licensed in the next two years), the physician needs to be able to place them within a complex landscape of drugs and a specific treatment strategy, which may be an "escalation" or "induction" approach. Whilst on treatment, neurologist and patient need to be vigilant to signs of disease breakthrough or adverse effects. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
